Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. (Q34518343)

2 August 2017

Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. (English)

1 reference

2 August 2017

1 reference

neoadjuvant chemotherapy

1 reference

Bacci G

1

1 reference

2 August 2017

Briccoli A

2

1 reference

2 August 2017

Ferrari S

3

1 reference

2 August 2017

Longhi A

4

1 reference

2 August 2017

Mercuri M

5

1 reference

2 August 2017

Capanna R

6

1 reference

2 August 2017

Donati D

7

1 reference

2 August 2017

Lari S

8

1 reference

2 August 2017

Forni C

9

1 reference

2 August 2017

DePaolis M

10

1 reference

2 August 2017

1 November 2001

1 reference

European Journal of Cancer

2 August 2017

1 reference

2 August 2017

37

1 reference

2 August 2017

2030-2039

1 reference

2 August 2017

16

1 reference

Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

[Effect of a local surgical procedure on the incidence of metastases following neoadjuvant chemotherapy of osteosarcoma]

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Neoadjuvant chemotherapy for pediatric osteosarcoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Soc

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarter

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Osteogenic sarcoma with clinically detectable metastasis at initial presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900229-5

7 January 2021

10.1016/S0959-8049(01)00229-5

Identifiers

DOI

1 reference

2 August 2017

1 reference